Intralesional rituximab for cutaneous manifestations of systemic B-cell lymphoma Nicole Maillet-Lebel, MD, Marie-Marthe Thibeault, MD, FRCPC JAAD Case Reports Volume 2, Issue 4, Pages 334-336 (July 2016) DOI: 10.1016/j.jdcr.2016.07.006 Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 A and B, Cutaneous lesions before intralesional rituximab. C and D, The result after the last treatment cycle. JAAD Case Reports 2016 2, 334-336DOI: (10.1016/j.jdcr.2016.07.006) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions